Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumours Including Sarcomas

Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumours Including Sarcomas

Full Title: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumours Including Sarcomas

Status: Active, Recruiting

Age Range: 12 - 85 years old

Locations:

  • Royal Manchester Children's Hospital, Manchester
  • University College London Hospital, London
  • The Riyal Marsden NHS Foundation Trust, London
  • Great North Children's Hospital, London

Trial Lead: Inhibrx Biosciences, Inc

Trial ID: NCT03715933

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

The study is supported by the European Commission’s FP7 health programme, Cancer Research UK and The University of Birmingham. More information about the trial can be found on their website

If you would like any more information on clinical trials in general, please contact us at The Bone Cancer Research Trust.


Donate now (This link opens in a new window) More about Ewing sarcoma